Details of the Drug
General Information of Drug (ID: DMDKSZ0)
Drug Name |
2-oxo-N-m-tolyl-2H-chromene-3-carboxamide
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1846-99-7; 2-oxo-N-(m-tolyl)-2H-chromene-3-carboxamide; 2-Oxo-2H-chromene-3-carboxylic acid m-tolylamide; N-(3-Methylphenyl)-2-oxo-2H-chromene-3-carboxamide; AC1LCCPQ; BAS 00837918; AC1Q2NKJ; 3-carboxamido coumarin, 8; TimTec1_006709; Oprea1_808053; Oprea1_256730; CBDivE_000076; MLS001209245; CHEMBL445184; SCHEMBL6228552; BDBM29158; 2h-1-benzopyran-3-carboxamide,n-(3-methylphenyl)-2-oxo-; MolPort-000-375-220; XUNAVIWFCXQWCJ-UHFFFAOYSA-N; HMS2825F09; HMS1553A21; ZINC130233; N-(m-Tolyl)-3-coumarincarboxamide; STK408207
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 279.29 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 3.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||
References